Ruth Wexler is an American industrial chemist best known as a co-discoverer of apixaban, a marketed anticoagulant; and losartan, a blood pressure treatment.
| Ruth R. Wexler | |
|---|---|
| Born | Pikesville, MD |
| Nationality | American |
| Alma mater | University of Pennsylvania |
| Known for | cardiovascular drug development |
| Scientific career | |
| Thesis | (1982) |
| Doctoral advisor | Amos Smith |
Education
Wexler received her B.A. in chemistry from Boston University in 1977, and a Ph.D. in organic chemistry working with Amos B. Smith at the University of Pennsylvania in 1982.
Research
Wexler started her career at DuPont in 1982, rising to Executive Director in 1998. She then joined Bristol-Myers Squibb as an Executive Director in 2001, moving eventually to New Jersey to head their cardiovascular research unit. She has worked on targets involved in apoptosis, inflammation, obesity, and coagulation. As of 2018, she has over 215 original research publications.
Awards
- 2015 - E.B. Hershberg Award for Discoveries in Medicinally Active Substances
- 2014 - Inducted into the ACS MEDI Hall of Fame
- 2011 - BMS Ondetti and Cushman Award
- 2004 - Outstanding New Jersey Woman in Research
References
- ^ Jarvis, Lisa. "E. B. Hershberg Award For Important Discoveries In Medicinally Active Substances | Chemical & Engineering News". cen.acs.org. Retrieved 2018-11-21.
- ^ "Ruth R. Wexler, Ph.D." www.acsmedchem.org. Retrieved 2018-11-21.
- "Wexler, Ruth | Amos Smith Research Group". www.sas.upenn.edu. Retrieved 2018-11-21.
- Quan, Mimi L.; Pinto, Donald J. P.; Smallheer, Joanne M.; Ewing, William R.; Rossi, Karen A.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Wexler, Ruth R. (2018-05-18). "Factor XIa Inhibitors as New Anticoagulants". Journal of Medicinal Chemistry. 61 (17): 7425–7447. doi:10.1021/acs.jmedchem.8b00173. ISSN 0022-2623. PMID 29775297.
- "MEDI Hall of Fame Inductees". www.acsmedchem.org. Retrieved 2018-11-21.